Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma

Timothy Best, Dalin Li, Andrew D. Skol, Tomas Kirchhoff, Sarah A. Jackson, Yutaka Yasui, Smita Bhatia, Louise C. Strong, Susan M. Domchek, Katherine L. Nathanson, Olufunmilayo I. Olopade, R. Stephanie Huang, Thomas M. MacK, David V. Conti, Kenneth Offit, Wendy Cozen, Leslie L. Robison, Kenan Onel

Research output: Contribution to journalArticlepeer-review

129 Scopus citations

Fingerprint

Dive into the research topics of 'Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds